2006;367(9526):1903-1912. 124. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the ef cacy and safety of new oral anticoagulants with warfarin in patients with atrial brillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. 125. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial brillation. N Engl J Med. 2011;364(9):806-817. 126. Freedman B, Lip GY. Unreal world or real world data in oral anticoagulant treatment of atrial brillation. Thromb Haemost. 2016;116(4):587-589. 127. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial brillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116(4):754-763. 128. Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial brillation: systematic review and meta-analysis. Stroke. 2017;48(4): 970-976. 129. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial brillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189. 130. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare bene ciaries treated with dabigatran or rivaroxaban for nonvalvular atrial brillation. JAMA Intern Med. 2016;176(11):1662-1671. 131. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial brillation. J Am Coll Cardiol. 2007;50(4):309-315. 132. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial brillation: an Asian perspective. Thromb Haemost. 2014;111(5): 789-797. 133. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial brillation: time for a reappraisal. Int J Cardiol. 2015;180:246-254. 134. Wang KL, Lip GY, Lin SJ, Chiang CE. 